Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7966054 | 0.87 | AKR1B1 (0.41) | PTGER4ALDH1A1CYP2C9CYP2C19HPGD | |
| SCHEMBL448107 | 0.85 | AKR1B1 (0.51) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL8120419 | 0.85 | AKR1B1 (0.51) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL15641295 | 0.85 | AKR1B1 (0.51) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL27890998 | 0.84 | AKR1B1 (0.50) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL17782926 | 0.83 | ALDH1A1 (0.50) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL18832089 | 0.83 | PTGER4 (0.45) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL28241058 | 0.81 | ALDH1A1 (0.48) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL1566758 | 0.81 | ALDH1A1 (0.48) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL15695555 | 0.81 | ALDH1A1 (0.48) | PTGER4ALDH1A1CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664255-B2 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-03-04 | — | — | US | disclosed |
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | TEXAS A&M UNIVERSITY SYSTEM, THE | 2010-05-06 | — | — | US | disclosed |
| WO-2010047774-A2 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS MALATE SYNTHASE, METHODS OF MARKING AND USES THEREOF | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | ME3, ME1, MDH1 | PTGER4 4122/4885ALDH1A1 620/4885CYP2C9 348/4885 |
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | ME3, ME1, MDH1 | PTGER4 4122/4885ALDH1A1 620/4885CYP2C9 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.